Amylin’s Bydureon fails to impress in head-to-head trial

Shares of Amylin Pharmaceuticals dipped after the developer posted disappointing data from a new trial showing that its closely watched GLP-1 diabetes drug Bydureon managed to beat out a competitor but only matched two other standard treatments. In the study, patients taking Bydureon demonstrated a 1.5 percent drop in blood sugar, or A1C, slightly better than Januvia but only on par with the generic metformin and Takeda's Actos. Analysts weren't impressed, noting that the once-weekly...

Rival developers race to grab Type 2 diabetes market

If the FDA approves the once-weekly diabetes treatment exenatide (Bydureon) later this year, it may quickly face some strong competition from new drugs now in the pipeline, according to a review presented by Alan Garber of Baylor College of Medicine in Houston. Writing from the World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension in Prague, the peer-reviewed MedPageToday highlights taspoglutide--which is now in Phase III--as well as albiglutide and LY2189265,...